Compare PepsiCo, Inc. (PEP) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs GeneDx Holdings Corp — how do they compare? PepsiCo, Inc. trades at $137.35 (market cap $188.97B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: PepsiCo, Inc. is far larger — about 73.8× GeneDx Holdings Corp's market cap, and PepsiCo, Inc. pays a 4.28% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| PEP | WGS | |
|---|---|---|
Market Cap | $188.97B | $2.56B |
Sector | Consumer Staples | Technology |
52-Week High | $170.44 | $167.51 |
52-Week Low | $134.95 | $34.51 |
Enterprise Value | $231.47B | $2.60B |
Dividend Yield | 4.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $138.45, up 0.6% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company maintains strong profitability with a 10.78% net margin and 51.59% ROE, though recent earnings beat expectations. Revenue grew to $93.93B in 2025, with a forward consensus price target of $158.79. Recent news highlights price cuts on snacks to address consumer pushback and a sponsorship withdrawal from a music festival.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside, but technical bearishness and pricing strategy risks weigh. Investment appeal hinges on execution of North American turnaround and margin expansion. Key risks include competitive pressures and volatile cash flows. The stock offers a dividend yield near 4%, appealing for income-focused investors amid steady growth prospects.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
